




The Wall Street Journal news department was not involved in the creation of this content.

PRESS RELEASE | July 11, 2013, 7:06 a.m. ET

Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.

Email Printer Friendly Share:

Text



ESTERO, Fla., July 11, 2013 /PRNewswire/ -- On May 16, 2013, United States District Court for the Eastern District of North Carolina DISMISSED with prejudice all claims for copyright and patent infringement asserted by plaintiffs Cornerstone BioPharma, Inc. ("Cornerstone") and J-Med Pharmaceuticals, Inc. ("J-Med") against Vision Pharma, LLC ("Vision"), Sander Busman, Thomas DeStefano, and Michael McAloose. The dismissal followed the decision of the United States Court of Appeals for the Federal Circuit, upholding the USPTO Board of Patent Appeals and Interferences' rejection of U.S. Patent No. 6,270,796, the sole patent asserted in the case. See *In re J-Med Pharmaceuticals, Inc.*, No. 11-1415 (Fed. Cir.). On January 11, 2013, the USPTO issued an Ex Parte Reexamination Certificate cancelling all claims of the '796 Patent.

"We were very confident from the absolute beginning that Vision, Thomas DeStefano, Michael McAloose and I would receive a most favorable outcome regarding Cornerstone and J-Med's case against us. Although these results are especially pleasing, this decision should not have taken so long to happen," said Sander S. Busman, Founder, President & CEO, Vision Pharma. Vision Pharma was represented by Ben Pleune and David Alban of Alston & Bird, LLP.

About Vision Pharma

Vision Pharma specializes in niche, generic pharmaceuticals with various delivery options and dosage forms. The company provides quality products at competitive prices while improving the lives of those who take their medicines. The organization's customer service acts promptly to requests while continuously improving to fulfill each customer and patient need. Maintaining additional inventory ensures Vision's ability to provide increased service levels. The pipeline of generic pharmaceuticals planned to market continues to be a strong focus internally and with other pharmaceutical organizations, domestically and internationally. Valuable relationships that are built show true dedication to each partnering company. You can count on Vision Pharma to consider the patient's safety as a top priority when developing and manufacturing their items. To learn more, please visit www.visionpharma.com.

Media Relations Contact:

Sander S. Busman

Vision Pharma

Founder, President & CEO

sbusman@visionpharma.com

SOURCE Vision Pharma

/Web site: <http://www.visionpharma.com>

Mortgage Rates Hit 3.10%

White House Program Cuts Up to \$1k off Monthly Payments! (3.40% APR)
www.SeeRefinanceRates.com

Warren Buffett Confesses

Warren Buffetts Shocking Confession Will Change your Investing Strategy
www.MarketTrendSignal.com

The End Of Obama?

This looming scandal could ruin the 44th President and disrupt the...

Editors' Picks



New Touch for iPhone



Candy-Colored Upgrade



Flop at the Box Office Spawns a Generation of 'Midnight Madness'



Eiji Toyoda, Driver of Global Expansion, Dies at 100



A Dawn Interrupted



[Subscribe](#) / [Login](#)

[Back to Top](#)

Customer Service

- Customer Center
- New!** Live Help
- Contact Us
- WSJ Weekend
- Contact Directory
- Corrections

Policy

- Privacy Policy
- Data Policy
- Copyright Policy
- Subscriber Agreement & Terms of Use
- Your Ad Choices

Advertise

- Advertise
- Place a Classified Ad
- Sell Your Home
- Sell Your Business
- Commercial Real Estate Ads
- Recruitment & Career Ads
- Franchising
- Advertise Locally

Tools & Features

- Apps
- Newsletters and Alerts
- Graphics & Photos
- Columns
- Topics
- Guides
- Portfolio
- Old Portfolio

More

- Register for Free
- Reprints
- Content Partnerships
- Conferences
- SafeHouse
- Mobile Site
- News Archive